Peptides and pregnancy: what the research actually reports
Pinealon, Semax, Epitalon, Cortexin and immune peptides have a wider reproductive research history than a short safety label suggests. This review separates the experimental methods, measured findings and unresolved questions.
Updated 8 November 2026; source checks began 7 November. The starting bibliography contains 24 journal, conference and monograph references plus 12 dissertation leads. References include translations, overlapping programs and secondary reports; they are not 36 independent trials. The source reviews below add related original offspring and cell studies.
These sources do not establish a safe pregnancy regimen for the investigational peptides discussed here. Selected benefits in an injured rat, changes in a culture dish and historical human exposure answer different questions. Pregnancy decisions need compound-specific clinical assessment; reported experimental doses below describe methods.
Evidence at a glance: who received the peptide?
| Evidence | Examples | What was reported | Main limit |
|---|---|---|---|
| Maternal animal exposure | Pinealon, 2008 / 2012 | Offspring growth, behavior and neuronal injury responses; elevated homocysteine persisted | Selected endpoints after induced injury; no established human fetal safety |
| Maternal exposure without induced hypoxia | Epitalon, 2007 | Altered brain morphometry, lower day-40 weight and more anxiety-related behavior | Five treated dams; increased structural measurements are not proven benefits |
| Historical human exposure | Thymalin / Thymogen anemia program; Imunofan bundled care | Clinical and biomarker signals; important neutral outcomes | Co-interventions, selection, historical comparisons and incomplete safety ascertainment |
| Treatment after birth | PGP, Selank, Dalargin, neonatal Cortexin | Some behavioral or tissue effects; residual deficits and transient benefits | Does not test giving the peptide to pregnant mothers |
| Nonpregnant reproductive physiology | Epitalon, Epithalamin, Pinealon | Region-specific neurotransmitter-rhythm changes | No demonstrated pregnancy or live-birth benefit |
| Embryonic-cell experiments | Semax, Selank, glyprolins | Survival, proliferation and differentiation effects in mouse cells | Cannot establish whole-pregnancy safety |
Pinealon during pregnancy: what the rat experiments measured
Two often-cited experiments ask whether maternal Pinealon changes the consequences of a prenatal insult. They do not ask whether healthy pregnant people can use Pinealon safely. The 2008 study induced hypoxia on gestation day 10; the 2012 study used methionine loading. Their treatment schedules, offspring ages and outcome measures differ. They cannot be combined into a single treatment effect.
Maternal exposure in animals · 2008 · Original journal publication
Pinealon after maternal hypoxia: offspring and adult-rat findings ↗
Pinealon-treated hypoxic dams had 14±2 offspring versus 9±3 with saline (p<0.05). Offspring activity and neuronal responses changed. Adult-rat Table 1 reports 10% mortality with both Pinealon and saline, conflicting with the narrative claim of higher Pinealon mortality.
Methods and population
Pregnant rats exposed to hypoxia on gestation day 10; separate adult-male experiment, n=10/group; offspring open-field strata n=6, 11, 9 and 12
Two distinct experiments: five-day pretreatment in adult males, and maternal Pinealon after gestation-day-10 hypoxia. Offspring cerebellar cells tested at day 12; open-field behavior at four weeks, stratified by maternal hypoxia sensitivity.
Maternal experiment: hypoxia on gestation day 10, then Pinealon 10 µg/kg intraperitoneally on five alternate days; saline comparator. Adult males: each peptide 10 µg/kg/day intraperitoneally for five days before hypoxia. These are distinct experimental schedules, not human-use instructions.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Offspring per dam | 14 ± 2 versus 9 ± 3 | Pinealon after maternal hypoxia versus saline · Birth · p<0.05; number of dams and meaning of ± not explicitly supplied |
| Horizontal activity, offspring of sensitive dams | 53 ± 5.1 versus 36 ± 6.9 | n=11 versus n=6 offspring · Four weeks · p<0.05 |
| Adult-male respiration arrest | 184 ± 30 versus 72 ± 10 seconds | Pinealon versus saline; n=10/group · After five-day pretreatment · p<0.014 |
| Adult mortality: table versus prose | Table 1: saline 10%, Pinealon 10%, Vilon 20%, Vesugen 10%, Epitalon 20% | Narrative says higher mortality with Pinealon; discrepancy unresolved |
| Oxidative readouts | Lower cell death did not consistently correspond to lower ROS | H₂O₂ and NMDA responses differed; exact figure bars not digitized |
What this can establish
- Animal injury experiments do not establish human pregnancy safety. Epitalon, Vilon and Vesugen were tested only in the adult-male arm of this paper.
- Number of pregnant dams, randomization, masking and litter-adjusted statistics are not established. Offspring are not independent maternal exposures.
- Table 1 mortality conflicts with the prose; do not convert the latter into a verified excess risk. Vilon and Epitalon respiration findings marked p<0.08 are not demonstrated p<0.05 results.
- The paper prints an Epitalon sequence ending in Arg; established Epitalon identity is Ala-Glu-Asp-Gly. That apparent source error is retained as an identity warning.
Source review: Original four-page PDF; methods and Tables 1–2 visually verified, printed pp.7–9. Journal year 2008, despite later index date.. Checked 8 November 2026.
Full extraction and original numerical tables ↗ · Original source ↗
Maternal exposure in animals · 2012 · Original journal publication
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia ↗
At day 10, pups weighed 25.03±4.86 g with maternal Pinealon plus methionine versus 17.86±3.05 g with methionine alone. First-trial maze latency improved partly, but homocysteine stayed elevated and all groups converged by trial five.
Methods and population
Six litters per group; 23 offspring/group in water-maze testing; plasma homocysteine subsets n=5, 4 and 4
Female Wistar rats, 180–200 g; intact, methionine-loaded and methionine-plus-Pinealon groups. Maternal pretreatment; neuron assays at offspring day 10 and Morris water maze at day 45. Mean±SD. Kruskal–Wallis, Fisher and Duncan tests; p<0.05 threshold.
Pregnant rats received methionine in drinking water, 1±0.01 g/kg/day, from the stated second trimester to the experiment end. Pinealon 10 µg/kg/day intraperitoneally for five days before methionine loading. No exact gestation-day numbers supplied. Flow cytometry: 5 mM H₂O₂ for 30 minutes, DCF-DA and propidium iodide; triplicate 10,000-event samples from at least two families. Historical laboratory protocol, not a pregnancy regimen.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Offspring weight | 25.03 ± 4.86 g versus 17.86 ± 3.05 g | Methionine+Pinealon versus methionine; intact 23.05 ± 1.45 g · Postnatal day 10 · p<0.05 versus methionine |
| Homocysteine remained elevated | 10.5 ± 0.2 versus 9.8 ± 0.2 µM | Pinealon+methionine n=4 versus methionine n=4; intact n=5: 5.6 ± 0.6 · Offspring day 45 · Both exposed groups p<0.05 versus intact; normalization not observed |
| First-trial platform latency | 137 versus 170 seconds; intact 112 seconds | Pinealon+methionine versus methionine · Second maze day, trial 1 · Pinealon differs from both other groups, p<0.05 |
| Later learning trials | Trials 2–4 favored Pinealon versus methionine; no group difference at trial 5 | Different swimming velocities complicate attribution to memory alone |
| Neuronal injury after H₂O₂ | PI-positive cells 7.0 ± 0.9% versus 17.7 ± 2.1% | Pinealon+methionine versus methionine; cell assays from offspring · Day-10 cerebellar cells; 30-minute challenge · p<0.05 |
What this can establish
- Maternal pretreatment in an injury model is not evidence that Pinealon is safe or effective in human pregnancy.
- No healthy Pinealon-only group, reported masking or randomization; litter clustering is not addressed. Six litters, not 23 independent maternal exposures per arm.
- The methods specify five pretreatment days before methionine, while other prose calls treatment simultaneous. Exact gestational treatment days are not supplied.
- Maternal homocysteine values 33.0±3.9 and 5.9±1.8 µM are cited prior-model findings, not newly measured treatment effects. Ten thousand flow-cytometry events are not ten thousand animals.
- Congenital anomalies, placental transfer, miscarriage risk and long-term human development were not systematically assessed.
Source review: Original seven-page publisher PDF; methods and Tables 1–3 visually checked, printed pp.180–183; narrative maze results checked. Mean±SD.. Checked 8 November 2026.
Full extraction and original numerical tables ↗ · Original source ↗
Maternal exposure in animals · 2012 · Original journal publication
Pinealon during gestation: survival, learning and caspase-3 ↗
The publisher abstract reports improved newborn survival and reduced learning disruption after maternal Pinealon, with effects varying by hypoxia timing. It gives no numerical treatment effect or group denominator.
Methods and population
Offspring of prenatally hypoxic rats, tested at 21 days; sample sizes absent from accessible abstract
Maternal treatment throughout pregnancy; prenatal hypoxia during different developmental windows; offspring behavior and brain caspase-3 measurements.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Survival and behavior | Qualitative improvement; prefetal/fetal hypoxia produced worse outcomes | Exact percentages and n unavailable in publisher abstract |
| Caspase-3 | Activity changed with developmental timing; a reduction alone does not prove reduced pathological cell death |
What this can establish
- Publisher abstract only; numerical outcomes, allocation and litter handling require full text.
- The abstract prints Lys-Glu-Arg, conflicting with established Pinealon Glu-Asp-Arg. Preparation identity needs clarification.
- Russian Neirokhimiya and English Neurochemical Journal versions describe one paper, not two replications. The 2013 Abramchuk dissertation and conference reports may share this program.
Source review: Original publisher abstract and translation metadata; full paper not recovered. Checked 8 November 2026.
Epitalon pregnancy study: structural changes with concerning functional findings
The recovered 2007 scan is more informative than its citation. Five pregnant rats received Epitalon late in gestation, without an induced hypoxic injury. Their offspring had larger measurements in selected brain regions, but lower body weight at day 40 and behavior interpreted as increased anxiety. Brain size, cortical thickness and neuronal nuclear size are not interchangeable with improved cognition. Epithalamin, a pineal extract, was not the intervention in this experiment.
Maternal exposure in animals · 2007 · Original journal publication
Epitalon in pregnant rats: altered brain development and behavior ↗
At day 40, exposed offspring weighed 73.6±2.6 g versus 83.4±4.9 g in pooled controls. Cortical measurements increased, while behavior at day 30 suggested less exploration and more anxiety. Larger brain measurements were not demonstrated benefits.
Methods and population
44 pups from five treated dams; control offspring n=16 from three intact dams and n=14 from two saline-treated dams. Day-1 and day-40 tissue groups n=36 and n=38 overall.
Pregnant rats received two Epitalon injections on gestation days 18 and 20; pooled intact/saline offspring controls. Histology at postnatal days 1 and 40, elevated-plus-maze behavior at day 30. No hypoxic injury was induced.
Epitalon 10 µg per pregnant dam intramuscularly on gestation days 18 and 20, 0.1 mL solution. This is per animal, not per kilogram. Intact and equal-volume saline offspring controls pooled after no detected difference. Histomorphometry and nucleic-acid microphotometry; elevated plus maze. Historical experiment, not human-use instructions.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Offspring body weight | 73.6 ± 2.6 g versus 83.4 ± 4.9 g | Epitalon-exposed versus pooled control offspring · Day 40 · Narrative describes significantly reduced growth; exact p-value/uncertainty type not specified |
| Parietal cortex thickness | 1528 ± 34 versus 1350 ± 36 µm | Exposed versus pooled controls · Day 40 · Described as significant; exact p-value absent |
| Layer I thickness / layer II neuron count | 137 ± 2 versus 129 ± 2 µm; 21.3 ± 0.8 versus 16.9 ± 0.5 cells per standard field | Measurements are structural differences, not proof of improved function · Day 40 |
| Behavioral direction | Less exploration and open-arm activity; more time in closed arms, grooming and sniffing | Authors interpret reduced exploratory activity and increased anxiety · Day 30 |
| Neutral findings | No significant body-weight differences at days 1, 14, 21 or 30; no absolute brain/hemisphere weight difference at days 1–40 |
What this can establish
- Small maternal sample: five treated dams, three intact and two saline dams. Pup counts must not be presented as independent pregnancies.
- Random allocation, masking, sex-stratified analysis and litter-adjusted statistics are not established. Numerical behavioral scores are absent.
- Reduced growth and increased anxiety-related behavior prevent describing these results as uniformly neuroprotective or as pregnancy-safety evidence.
Source review: Original two-page scanned article; both pages visually inspected, including all methods and numerical results. Checked 8 November 2026.
Cortexin, Pinealon and Deltaran: conference results and dissertation detail
The Rostov program compared peptide effects across developmental windows, survival, learning and brain chemistry. The 2014 Sudak proceedings provide an original conference abstract; the 2013 Abramchuk source is a third-party transcription of an author’s abstract. Their shared authors and models make cohort overlap plausible, but do not prove whether samples were reused. Neither is counted as independent replication of the 2012 paper. Caspase-3 has developmental as well as cell-death functions; changing its activity does not by itself demonstrate neuroprotection.
Deltaran contains DSIP with glycine; it is linked to the DSIP family card with that formulation distinction. Original Deltaran formulation description ↗
Maternal exposure in animals · 2014 · Conference abstract
Pinealon, Cortexin and Deltaran: prenatal-stress conference findings ↗
The abstract reports 96% survival with Deltaran and 94% with Pinealon, without denominators or an untreated-hypoxia survival rate. Learning favored Deltaran then Pinealon then Cortexin, but contradictory caspase-3 statements remain unresolved.
Methods and population
21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied
Maternal intraperitoneal exposure throughout pregnancy. Daily hypobaric hypoxia on gestation days 13–20, 66.41 kPa for three hours. Offspring Morris maze and cortical/brainstem caspase-3 at day 21.
Maternal doses as printed: Cortexin 1 mg/kg, Pinealon 10 µg/kg, Deltaran 12 µg/100 g body weight; intraperitoneally throughout gestation. The abstract does not resolve whether Deltaran mass means formulation or active peptide. These are historical animal methods.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Reported survival | Deltaran 96%; Pinealon 94% | No n, uncertainty, untreated-hypoxia rate or numerical Cortexin survival supplied |
| Latent learning | Authors rank Cortexin < Pinealon < Deltaran | No group mean latency, variance or between-treatment p-values |
| Caspase-3 conflict | Deltaran+hypoxia is described as +144% in cortex and +109% in brainstem, then as remaining at control level | Both statements occur in the same abstract; do not resolve by assumption · First sentence: p<0.0001 and p<0.001, respectively |
| Comparator gap | Seven-group list lacks a hypoxia-only untreated arm | An omitted group may exist, but it cannot be reconstructed from the abstract |
What this can establish
- Conference abstract with missing denominators and an internally inconsistent biochemical result; not a clinical trial.
- Deltaran is a DSIP-containing formulation with glycine; results are not proof for isolated DSIP. Formulation mass versus active-peptide mass is not resolved by this abstract.
- Shared Rostov authors and models may overlap the 2012 papers and dissertations; no pooled sample or independent-replication count is calculated.
Source review: Original congress proceedings reproduced by an academic repository; printed pp.233–234 visually checked. Checked 8 November 2026.
Maternal exposure in animals · 2013 · Dissertation author-abstract transcription
Pinealon versus Cortexin after prenatal hypoxia: dissertation methods ↗
For gestation-day-13–20 hypoxia, third-day maze latency was 34.5±3.9 seconds with Pinealon, 58.37±3.22 with Cortexin and 121.8±19.01 with saline. Cortexin-only offspring also performed worse than intact controls. Source is an author-abstract transcription, not an authenticated full thesis.
Methods and population
Young-rat prenatal arm and a separate 120-old-male ischemia arm; prenatal Table 2 contains two n values per group with unclear hierarchy
Maternal treatment throughout gestation; hemic and hypoxic injury windows compared. Offspring killed at days 21–23; Morris maze, brain HPLC monoamines and fluorimetric caspase-3. Older-rat carotid occlusion is a separate experiment.
Pinealon 10 µg/kg or Cortexin 1 mg/kg administered maternally throughout gestation; saline controls; injury windows include gestation days 1–10, 18–20 and 13–20. Separate older-rat pretreatment doses must not be substituted for the prenatal schedule.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Third-day maze latency, late prenatal hypoxia | Pinealon 34.5 ± 3.9 s; Cortexin 58.37 ± 3.22 s; saline 121.8 ± 19.01 s | Intact 18.72 ± 1.73 s; table n=15/(60), n=15/(60), n=7/(28), intact n=18/(72) · Third testing day · Table # denotes within-group day 3 versus day 1, not a treatment-versus-control test |
| Cortexin without hypoxia | 38.55 ± 2.34 s versus intact 18.72 ± 1.73 s | Author reports 106% longer latency; no benefit in this healthy comparison · Third testing day · p<0.01 in narrative |
| Survival | Pinealon reduced stillbirths in some models; residual loss remained in the longest hypoxia window | Exact independent dam denominators and complete cohort flow unresolved |
What this can establish
- Third-party transcription of the author’s abstract, not the complete original thesis; verify the scan before relying on uncertain table formatting.
- Two n values per prenatal group are not adequately explained; animal, dam, litter and repeated-trial denominators cannot be reconciled.
- Related journal/conference publications may share these cohorts. Within-group learning p-values do not demonstrate between-drug superiority.
- The prose and table indicate incomplete protection, including impaired Cortexin-only learning; neither compound has demonstrated human pregnancy safety here.
Source review: Author-abstract text and Table 2 reproduced by Medical-Diss; original full dissertation and table scan not authenticated. Checked 8 November 2026.
Semax in pregnant rats: combination treatment and missing effect sizes
The 2001 report explicitly studied Semax with β-casomorphin-7. The 2003 brain-amine abstract also names both heptapeptides but does not isolate a Semax-specific result. Reported prevention of growth or biochemical disturbances therefore belongs to the tested peptide intervention, with its attribution limits. The 2002 Russian synthesis and 2003 English translation are one source, not two trials.
Maternal exposure in animals · 2001 · Original journal publication
Peptidergic correction of the effect of acute hypobaric hypoxia in pregnant rats on progeny ↗
Maternal Semax plus β-casomorphin-7 reportedly prevented delayed pup growth, weight gain, eye opening and behavioral changes after acute hypoxia. The checked abstract provides no numerical effect sizes.
Methods and population
Pregnant albino rats and offspring after acute hypobaric hypoxia; n unavailable in abstract
Maternal intranasal peptide exposure around an acute prenatal hypoxic insult; postnatal growth/behavior or brain monoamines evaluated.
Intranasal maternal peptide exposure. The 2003 abstract specifies a single administration; doses and exact exposure timing are not supplied in the checked abstracts.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Growth and eye opening | Delayed by hypoxia; authors report prevention with the peptide mixture | |
| Behavior | Hypoxia-associated changes reportedly prevented; exact tests and scores not supplied |
What this can establish
- The 2001 intervention is explicitly a Semax plus β-casomorphin-7 mixture; the 2003 abstract does not isolate compound-specific effects.
- No verified sample sizes, effect magnitudes, randomization, masking or systematic reproductive-safety assessment in the checked abstract.
- Related papers from one laboratory do not establish independent replication or human pregnancy safety.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Maternal exposure in animals · 2003 · Original journal publication
Effect of acute progestational hypoxia on the content of biogenic amines in the brain of albino rat pups: Peptide correction ↗
Maternal intranasal Semax and β-casomorphin-7 were reported to prevent age-dependent disturbances of offspring brain amines. Exact concentrations, group sizes and peptide-specific effects are unavailable in the abstract.
Methods and population
Pregnant albino rats and offspring after acute hypobaric hypoxia; n unavailable in abstract
Maternal intranasal peptide exposure around an acute prenatal hypoxic insult; postnatal growth/behavior or brain monoamines evaluated.
Intranasal maternal peptide exposure. The 2003 abstract specifies a single administration; doses and exact exposure timing are not supplied in the checked abstracts.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Offspring catecholamines | Age-dependent brainstem/cortical disturbances reportedly prevented | No numerical concentrations or separate compound effects supplied |
What this can establish
- The 2001 intervention is explicitly a Semax plus β-casomorphin-7 mixture; the 2003 abstract does not isolate compound-specific effects.
- No verified sample sizes, effect magnitudes, randomization, masking or systematic reproductive-safety assessment in the checked abstract.
- Related papers from one laboratory do not establish independent replication or human pregnancy safety.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Review / overlapping experimental program · 2003 · Review and translated source
The effects of ante- and postnatal hypoxia on the central nervous system and their correction with peptide hormones ↗
The synthesis describes poorer postnatal learning and hyperactivity after hypoxia and improvement with a peptide constellation. It supplies no extractable trial-level numerical effect.
Methods and population
Review/synthesis of ante- and postnatal hypoxia experiments; no new cohort established
Review/synthesis; English translation of the 2002 Russian Physiological Journal article, 88(2):184–190.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Development and behavior | Qualitative peptide-constellation benefit described; not an independently established new experiment |
What this can establish
- Russian 2002 original and English 2003 translation must be counted once.
- Related experimental papers from the same research program may overlap; the review supplies no independent replication or human safety estimate.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Thymalin, Thymogen and Imunofan: human exposure with major design limits
Historical human exposure deserves examination, but it does not automatically establish a current obstetric indication or fetal safety. The anemia program added immunomodulators to iron and vitamins; its small Thymalin prevention subgroup is different from its larger treatment comparison. The Imunofan paper evaluates risk-stratified bundled care, with the peptide only in one subgroup. The monograph summarizes older cohorts rather than enrolling a new one. These sources do not justify replacing established obstetric care.
Historical human pregnancy exposure · 1995 · Dissertation author-abstract transcription
Thymalin and Thymogen in gestational anemia: historical human comparisons ↗
In the 24-woman prevention subgroup, anemia by week 36 was reported in 2/12 Thymalin-treated women versus 6/12 controls. The larger treatment program described fewer obstetric complications, but did not isolate each peptide or establish randomized effects.
Methods and population
520 women in the overall research program; treatment comparisons: conventional care n=70, adjunct Thymalin/Thymogen n=140, conventional care plus heparin n=60. Separate prevention subgroup: 12 Thymalin versus 12 controls.
Historical clinical and experimental dissertation program; women aged 17–40. Iron/vitamins as background treatment; separate heparin group; 100-woman longitudinal biomarker subgroup and HLA-selected 24-woman prevention comparison. These overlapping subsets must not be added to the program total.
Adjunct Thymalin or Thymogen with iron and vitamins. Prevention subgroup: five-day Thymalin courses reported at weeks 20 and 28, monitoring through week 36. Recommendation section gives different timing (16 and 24 weeks). Historical methods are not current obstetric guidance.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Prevention subgroup: anemia | 2/12 with Thymalin versus 6/12 controls | HLA-selected risk subgroup; control anemia included four mild and two moderate cases · Gestation week 36 · No randomized allocation, confidence interval or inferential p-value established |
| Treatment-program complications | Authors report 1.72-fold lower frequency of selected delivery complications | Combined immunomodulator regimens versus conventional care; no compound-specific raw event table verified · Narrative p<0.05; not a verified independent peptide risk reduction |
| Time to clinical improvement | Reported 4.2 ± 0.6 days earlier with immunocorrective care | Compared with heparin or conventional treatment; bundled clinical/laboratory/ultrasound measures |
| Animal arm: separate evidence | Pregnant-rat erythrocyte and reticulocyte changes also reported | Animal results are not patient outcomes; erythrocyte-derived experimental peptides are not Thymalin or Thymogen |
What this can establish
- Historical nonrandomized multimodal care; the study does not establish efficacy or safety of either peptide in current pregnancy care.
- Third-party author-abstract transcription, not an authenticated 313-page thesis with 49 original tables. Treatment-arm sizes for Thymalin and Thymogen individually are not supplied.
- The 12/12 prevention comparison is small and selected. Claims of 83.3% prevention lack a randomized counterfactual and must not be advertised as treatment efficacy.
- Narrative prevention timing is weeks 20 and 28; recommendation section says weeks 16 and 24. The schedules conflict. No comprehensive congenital-anomaly or long-term child-safety assessment is available.
Source review: Medical-Diss transcription of the author’s abstract; methods and clinical/prevention results checked; full original thesis not recovered. Checked 8 November 2026.
Historical human pregnancy exposure · 2023 · Original journal publication
Imunofan in risk-stratified obstetric care: 112-woman program ↗
The program reports threatened pregnancy loss falling from 41.3% to 19.6% and preterm birth from 8.7% to 4.7%. Imunofan was an adjunct only in the 36-woman middle-risk protocol; these overall results cannot be assigned to Imunofan.
Methods and population
112 women with latent herpesvirus infection: low-risk n=27, renal-inflammatory disease n=36, prior reproductive loss n=49; historical cohorts n=24 and n=42 discussed separately
Risk-stratified clinical program compared with earlier protocols; all groups received immunoglobulin, and the highest-risk group also plasmapheresis. Table 1 labels the n=112 dataset Nikitin 2017, although the article was published in 2023. No randomized Imunofan-only comparator.
Imunofan intramuscularly in the medium-risk group, 2–4 weeks after completion of first-trimester immunoglobulin treatment. Immunoglobulin courses at weeks 8–12 and 20–24 in that group. Other risk groups followed different protocols; this is a historical bundled-care description.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Threatened pregnancy loss | 41.3% / 19.6% | Table’s without/after immunocorrection columns for the n=112 program; not the n=36 Imunofan subgroup · Table star: p<0.05 |
| Preterm birth | 8.7% / 4.7% | Same whole-program columns; raw event denominators not supplied · Table star: p<0.05 |
| Neonatal morbidity | 638.0 / 264.0 per 1,000 | Morbidity rate, not percentage of infants; multiple diagnoses may occur · Table star: p<0.05 |
| Viral transmission | 54.5% / 18.2% | No significance star for this row; narrative significance claims are broader than table notation |
| Neutral outcomes | No reduction in overall gestational complications or spontaneous pregnancy loss; no significant effect on perinatal mortality | Explicit discussion statement on printed p.47 |
What this can establish
- Imunofan-specific effects cannot be isolated: different baseline risks, immunoglobulin exposure, plasmapheresis and historical comparisons confound the program outcomes.
- The 112 women are not an Imunofan treatment arm. Only the n=36 risk-group protocol explicitly adds it, and subgroup outcomes are not separately supplied.
- Publication year 2023 is not recruitment year: the outcome table labels these data 2017. No raw outcome counts, confidence intervals or systematic long-term child-safety follow-up were verified.
- The paper reports important neutral outcomes. Historical exposure does not establish a current indication or safety during pregnancy.
Source review: Original publisher PDF text, methods, Table 1 and discussion checked via indexed full text; numerical table not visually verified. Checked 8 November 2026.
Secondary summaries of human obstetric exposure · 2007 · Historical monograph / secondary source
Thymogen in obstetrics: historical reports summarized in a monograph ↗
The monograph reports a positive clinical response in 89.7% of a 29-woman gestosis series, but only 25 were followed to delivery: 21 term, two post-term and two preterm births. These are historical uncontrolled summaries, not a new trial.
Methods and population
Secondary summaries include 29- and 63-woman pregnancy series; other cohorts and anemia/infection programs discussed
Narrative monograph collating obstetric and gynecological programs. One cited series: 17 women with edema, 12 with mild nephropathy. Another: 63 women receiving adjunct Thymogen with conventional treatment. Healthy controls in other reports do not substitute for untreated disease controls.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| 29-woman series | 89.7% reported clinical response; delivery follow-up in 25/29 | 21 term, 2 post-term, 2 preterm; four women lack delivery follow-up in this summary |
| 63-woman series | 89% reported aggregate clinical response | Concurrent conventional therapy; no controlled effect estimate |
| Reported adverse events | None reported in the 29-woman summary | Small sample and limited follow-up cannot establish reproductive safety |
| Source transcription conflicts | Another summary prints 100 mg instead of the surrounding 100 µg and gives a notably different birth-weight uncertainty | Do not silently harmonize or use the anomalous units as a clinical regimen |
What this can establish
- Secondary source from a product-associated host; original cited papers and complete cohort protocols are still needed. Do not count it as an independent trial.
- No established random allocation, blinded assessment or appropriate untreated disease control in the quoted series.
- Clinical-response definitions and pregnancy-safety ascertainment are limited; small uncontrolled reports do not establish maternal or fetal safety.
Source review: Original 16-page monograph PDF indexed text; gestosis chapter and source structure checked; no independent full-paper appraisal of cited cohorts. Checked 8 November 2026.
Treatment after birth: PGP, Selank, Cortexin and Dalargin
Prenatal injury and prenatal drug exposure are different questions. In these experiments, the insult occurred before birth, but the peptide was administered to pups or adult offspring. A postnatal benefit cannot establish that the same compound crosses the placenta safely or protects a fetus when given to a pregnant mother. Residual deficits, transient effects and adverse findings in intact treated animals are included below.
Postnatal offspring treatment · 2006 · Original journal publication
Peptidergic correction of behavior in adult progeny of albino rats exposed to acute hypoxia during early organogenesis ↗
Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.
Methods and population
Rat offspring exposed to hypoxia on gestation days 9–10; n unavailable in abstract
Intranasal Pro-Gly-Pro to pups on postnatal days 13–15, 1 mg/kg; adult physical development, spontaneous behavior and training evaluated.
Pro-Gly-Pro 1 mg/kg intranasally to pups on postnatal days 13–15, following maternal hypoxia on gestation days 9–10. Research description, not human-use advice.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Female offspring | Authors report prevention of the measured negative behavioral consequences | |
| Male offspring: residual deficit | Most measured effects improved, but delayed physical development persisted |
What this can establish
- Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety.
- Sample sizes, numerical scores, masking and litter-level analyses unavailable in the checked abstract. Sex-specific qualitative results are not quantified effect estimates.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Adult offspring treatment · 2008 · Original journal publication
Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia ↗
Selank given to adult offspring increased sensory attention by a reported factor of 2–3 and facilitated learning 1.5-fold (both p<0.01). This was treatment after prenatal injury, not administration to pregnant mothers.
Methods and population
Adult rats exposed to antenatal hypoxia on gestation days 14–16; n not supplied in abstract
Adult-offspring behavioral and brain serotonin/noradrenaline assessment after prenatal hypoxia; Selank 300 µg/kg intraperitoneally.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Sensory attention | Reported 2–3-fold increase | p<0.01; no n or confidence interval supplied |
| Learning | Reported 1.5-fold facilitation | p<0.01 |
| Monoamine balance | Investigative behavior and serotonin/noradrenaline balance reportedly restored; exact concentrations absent |
What this can establish
- Adult offspring treatment cannot establish fetal safety of maternal Selank.
- The 2008 English article translates the 2006 Russian paper, PMID 17385425; these are not independent replications.
- Sample sizes, blinding, litter handling and numerical raw scores are unavailable in the checked abstract.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Postnatal offspring treatment · 2016 · Original journal publication
USING CORTEXIN TO MANAGE THE CONSEQUENCES OF PERINATAL HYPOXIC BRAIN INJURY IN INFANT RATS ↗
Cortexin transiently improved EMG spectral structure at day 10, but not amplitude; the EMG benefit was absent at day 30. Intact treated pups developed autonomic and heart-rhythm disturbances. This experiment began after birth.
Methods and population
Infant rats with injury induced at postnatal day 7, plus intact treated controls; n absent from abstract
Day-7 carotid ligation plus hypoxia; Cortexin 1 mg/kg intraperitoneally starting one hour later for ten days. EMG, ECG, respiration and heart-rate variability assessed 10 and 30 days after injury.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| EMG | Transient spectral improvement at day 10; no amplitude benefit; earlier EMG benefit absent at day 30 | |
| Autonomic outcomes | Day-30 autonomic balance favored treated injured animals, but intact treated pups showed disturbances | Direction differed by injury status |
| Respiration | Rate remained higher than intact controls in both injured groups |
What this can establish
- Neonatal treatment is not maternal or fetal exposure. Do not summarize this as a pregnancy-safety trial.
- Mixed benefits, transient effects and adverse physiological changes in intact pups must accompany positive findings.
- Sample sizes, numerical traces and effect estimates are not available in the checked abstract.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Postnatal offspring treatment · 2016 · Original journal publication
Correction of Negative Effect of Antenatal Hypoxia on Liver Tissue Homeostasis in Newborn Albino Rats with Opioid Peptides ↗
Neonatal Dalargin reportedly normalized liver growth/proliferation and nucleolar measures after prenatal hypoxia. The non-opioid analogue did not normalize all measures. Both reduced oxidative-stress indices; neither was administered to pregnant animals in this study.
Methods and population
Seven-day-old rats after antenatal hypoxia; peptide exposure on postnatal days 2–6; n absent from abstract
Dalargin or a non-opiate Leu-enkephalin analogue, 100 µg/kg on postnatal days 2–6; day-7 liver growth, proliferation, nucleolar and redox assays.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Dalargin | Reported normalization of gravimetric, proliferation and hepatocyte nucleolar measures | |
| Non-opioid analogue: incomplete effect | Gravimetric and nucleolar parameters not normalized; proliferating-cell pool increased | Related analogue is not Dalargin |
| Redox outcomes | Both preparations reduced free-radical oxidation and improved antioxidant defenses; numerical effects unavailable |
What this can establish
- Postnatal animal treatment, not maternal administration or human neonatal efficacy.
- Abstract gives no group n, exact numerical effects, comprehensive safety series or proof of normal adult liver function.
- The related analogue’s exact preparation must be verified separately before assigning its results to a specific NALE formulation.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Other maternal experiments: Thymalin and the non-opioid enkephalin analogue
The Thymalin abstract concerns offspring cortical changes in a maternal neurosensitization model. Lebedko’s author-abstract transcription describes maternal exposure to a non-opioid Leu-enkephalin analogue and a distinct Hydra morphogen. The original thesis and accurate preparation identity remain important acquisition targets. Dalargin is cited as background in the latter source; its findings are not silently substituted for those of the non-opioid analogue.
Maternal exposure in animals · 1989 · Original journal publication
Structural and cytochemical changes in cerebral cortical neurons of the offspring of neurosensitized female rats after prenatal administration of thymalin ↗
Maternal Thymalin reportedly prevented cortical neuronal degeneration and cell-density loss in offspring, with age-dependent protein changes. No numerical effect sizes or reproductive-safety outcomes are supplied.
Methods and population
Offspring of neurosensitized pregnant rats; n and gestational schedule absent from abstract
Gestational Thymalin course in neurosensitized dams, followed by age-related cortical histology/cytochemistry in offspring.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Cortical histology | Less dystrophic change, neuronal death and reduced cortical cell density described | |
| Cellular protein | Higher nuclear and especially cytoplasmic protein content; effects reportedly stronger in older offspring |
What this can establish
- Qualitative historical animal abstract; no verified group size, dose, allocation or quantitative histological effect.
- Disease-model cortical findings do not establish fetal safety, placental transfer or clinical benefit in pregnancy.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Maternal exposure in animals · 1994 · Dissertation author-abstract transcription
NALE and Hydra morphogen: maternal exposure and offspring lung findings ↗
Maternal non-opioid Leu-enkephalin analogue exposure reportedly restored offspring tracheal DNA synthesis after prenatal hypoxia and changed lung redox measures. The distinct Hydra morphogen inhibited tracheal DNA synthesis in uninjured offspring. Sequence transcription and full-thesis tables need authentication.
Methods and population
Author abstract describes 700 experiments on neonatal offspring of 160 dams; these are not 700 independent pregnancies. Treatment-specific dam/pup denominators unavailable.
Four exposure conditions for each peptide: uninjured, prenatal hypoxia, peptide alone, peptide plus hypoxia. Daily maternal hypoxia on gestation days 14–19; offspring examined 24 hours after birth. Separate non-opioid analogue and Hydra morphogen arms.
Non-opioid Leu-enkephalin analogue or Hydra peptide morphogen 10 µg/kg intraperitoneally to dams 30 minutes before daily hypoxic exposure on gestation days 14–19. Day-1 offspring tracheal DNA-synthesis and lung/blood redox assays. Experimental methods, not a human pregnancy regimen.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Non-opioid analogue plus hypoxia | Offspring tracheal DNA synthesis reportedly restored; neonatal lung catalase and superoxide-dismutase activity reportedly returned toward control levels | Qualitative/narrative extraction; per-group n and precise uncertainty not authenticated |
| Hydra morphogen alone: adverse direction | Tracheal epithelial DNA synthesis and part of antioxidant defense were suppressed in uninjured offspring | This is a different experimental peptide, not an effect assigned to NALE |
| Neutral assay findings | Glutathione reductase and glutathione transferase did not differ significantly across experimental groups | No universal improvement across all antioxidant endpoints |
What this can establish
- Historical maternal animal study; no human pregnancy efficacy or safety established.
- Third-party OCR transcription, not an authenticated 147-page thesis. Tables and peptide sequences contain OCR ambiguity; no precise table cells are treated as visually verified.
- NALE is a non-opioid analogue, distinct from Dalargin. The transcription prints a third residue resembling Glu, while later NALE sources specify Gly; exact preparation identity remains unresolved.
- The associated 1994 journal report may share these experiments and must not be counted as independent replication. Hydra morphogen has no interchangeable compound-card assignment.
Source review: Medical-Diss author-abstract transcription; selected methods, narrative results and source limitations checked; original full thesis not recovered. Checked 8 November 2026.
Reproductive-cycle studies: Epitalon, Epithalamin and Pinealon
These papers concern hypothalamic catecholamine rhythms and models of reproductive disruption in female rats. They provide a mechanistic research trail, without a verified pregnant cohort or live-birth outcome. The 2012 Epitalon/Epithalamin experiment used 1,2-dimethylhydrazine (DMH); the 2014 Pinealon paper used methionine-induced hyperhomocysteinemia. Those are separate models and different preparations.
Nonpregnant reproductive physiology · 2012 · Original journal publication
Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats ↗
Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.
Methods and population
Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract
Single 1,2-dimethylhydrazine exposure in female rats; region- and circadian-time-specific catecholamine measurements after melatonin or pineal-peptide interventions.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Epithalamin | Recovery of norepinephrine diurnal dynamics in medial preoptic area | Norepinephrine decreased between 09:30 and 11:00 circadian time |
| Epitalon | Dopamine remained low at 05:00 and increased by 11:00 circadian time | Median eminence/arcuate region; no numerical concentrations supplied |
| Pregnancy and fertility outcomes | No pregnant cohort, congenital-anomaly rate or verified live-birth benefit in the checked abstract |
What this can establish
- Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility.
- Epitalon is a defined tetrapeptide; Epithalamin is a bovine pineal peptide extract. Their findings are not interchangeable.
- Doses, n, allocation, quantitative effect sizes and adverse-event surveillance unavailable in the checked abstract.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Nonpregnant reproductive physiology · 2014 · Original journal publication
Pinealon and hypothalamic norepinephrine rhythms in female rats ↗
The publisher abstract reports correction of altered diurnal norepinephrine dynamics in the medial preoptic hypothalamic area. It does not provide n, numerical concentrations or pregnancy outcomes.
Methods and population
Female rats with methionine-induced hyperhomocysteinemia; pregnancy not established
Methionine loading and hypothalamic norepinephrine measurements across circadian times; adjacent reproductive-regulation experiment.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Norepinephrine rhythm | Qualitative correction described; no extractable numerical treatment effect | |
| Scope | Nonpregnant reproductive physiology; not a maternal/fetal exposure study |
What this can establish
- Abstract-level source; methods, individual timepoint values and full outcome table still require retrieval.
- A normalized neurotransmitter rhythm does not establish fertility, implantation, live-birth benefit or pregnancy safety.
Source review: Publisher-deposited abstract/citation; full paper requires retrieval. Checked 8 November 2026.
Embryonic-cell assays: useful mechanisms, incomplete safety evidence
Mouse embryonic stem-cell survival and differentiation are narrower endpoints than embryo-fetal development in an intact pregnancy. The 2017 abstract includes both favorable survival findings and reduced proliferation or GABA-positive differentiation. Its broad conclusion about absence of embryonic/fetal toxicity goes beyond what this model can establish.
Embryonic-cell experiments · 2017 · Original journal publication
Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells ↗
Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.
Methods and population
Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses
Cultured mouse embryonic stem cells; proliferation, survival during serum deprivation and neuronal differentiation after several peptides and growth-factor controls.
Reported findings
| Endpoint | Reported result | Comparator, timing and statistics |
|---|---|---|
| Selank neuronal differentiation | GABA-positive neuron ratio decreased by 61% | Selank 100 µM versus control; not an in-vivo malformation endpoint |
| PGP proliferation | Small but significant inhibition at 10 µM | No numerical inhibition magnitude in abstract |
| Semax cell survival | Increased survival at 10 and 0.1 µM during serum deprivation | Cell-stress endpoint, not reproductive toxicology |
| Safety-inference limit | The authors infer no embryonic/fetal toxicity; this culture model does not establish that claim in pregnancy |
What this can establish
- Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes.
- Reduced differentiation and proliferation findings must not be omitted from a safety summary.
- Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the checked abstract.
Source review: Indexed original abstract; full methods and outcome tables not recovered. Checked 8 November 2026.
Russian pregnancy and reproductive research bibliography
All 36 starting references are retained below, with access status and remaining gaps. A link to a related dissertation or translation is identified as such. Unretrieved citations do not receive invented results or separate thin study pages.
Regulatory Peptides Protect Brain Neurons from Hypoxia In Vivo
Kozina et al. 2008. Doklady Biological Sciences 418:7–10. DOI 10.1134/S0012496608010031
Original PDF checked
Maternal Pinealon arm and separate adult-male peptide comparison. Table/prose mortality conflict retained.
Checked source or related source review ↗Pinealon Protects the Rat Offspring from Prenatal Hyperhomocysteinemia
Arutjunyan et al. 2012. IJCEM 5(2):179–185. PMID 22567179
Original PDF and all three tables checked
Existing source upgraded; homocysteine remained elevated. Six litters per group; no human pregnancy cohort.
Checked source or related source review ↗Влияние короткого пептида на нейродегенеративные процессы у крыс, перенесших пренатальную гипоксию
Mendzheritskii, Karantysh, Abramchuk & Ryzhak. 2012. Neirokhimiya 29(3):229–234; English Neurochemical Journal 6(3):218–222. DOI 10.1134/S1819712412030105
Publisher abstract checked
English and Russian versions are one paper. Exact effect sizes and full methods missing; printed peptide sequence conflicts with EDR identity.
Checked source or related source review ↗Peptidergic Correction of the Effect of Acute Hypobaric Hypoxia in Pregnant Rats on Progeny
Maslova et al. 2001. BEBM 131(2):109–112. PMID 11391386
Original indexed abstract checked
Explicit Semax + β-casomorphin-7 mixture. No separate Semax effect estimate.
Checked source or related source review ↗Effect of Acute Progestational Hypoxia on the Content of Biogenic Amines in the Brain of Albino Rat Pups: Peptide Correction
Maslova et al. 2003. BEBM 136(2):123–125. PMID 14631488
Original indexed abstract checked
Maternal intranasal peptides; no quantitative monoamine table or treatment-arm n in accessible abstract.
Checked source or related source review ↗Влияние на центральную нервную систему анте- и постнатальной гипоксии и их коррекция пептидными гормонами
Maslova et al. 2002. Russian Physiological Journal 88(2):184–190
Russian-original citation; English version checked
Linked to reference 7 as the same translated source. University author bibliography uses “регуляторными пептидами” in the title; original title page still needed.
Checked source or related source review ↗The Effects of Ante- and Postnatal Hypoxia on the Central Nervous System and Their Correction with Peptide Hormones
Maslova et al. 2003. Neuroscience and Behavioral Physiology 33(6):607–611. PMID 14552554
English indexed abstract checked
Translation of reference 6; synthesis of the same laboratory program, not an independent replication.
Checked source or related source review ↗Пренатальный гипоксический стресс: физиологические и биохимические последствия, коррекция регуляторными пептидами
Sokolova, Maslova, Maklakova & Ashmarin. 2002. Usp Fiziol Nauk 33(2):56–67. PMID 12004578
Indexed review abstract checked
Broad review of nervous, respiratory and cardiovascular consequences; no independent new intervention cohort established from the abstract.
Влияние введения эпиталона беременным крысам на показатели развития мозга их 1- и 40-дневного потомства
Ryzhavskii & Nikolaeva. 2007. Far Eastern Medical Journal (2):131–132
Original scan recovered and visually checked
Author order corrected from the earlier bibliography. Reduced day-40 weight and anxiety-related behavior accompany larger brain morphometric measurements.
Checked source or related source review ↗Применение неопиатного аналога лей-энкефалина и пептидного морфогена гидры для коррекции нарушений пролиферации в эпителии трахеи и процессов ПОЛ в легких новорожденных крыс, подвергнутых пренатальной гипоксии
Lebedko & Timoshin. 1994. BEBM 117(5):535–537
Journal full text still needed
Related dissertation abstract recovered (reference 26). Its methods are not silently assigned to the unretrieved journal article; cohort overlap unresolved.
Checked source or related source review ↗Peptidergic Correction of Behavior in Adult Progeny of Albino Rats Exposed to Acute Hypoxia During Early Organogenesis
Graf et al. 2006. BEBM 142(1):32–34. PMID 17369896
Original indexed abstract checked
PGP administered to pups on days 13–15, not to mothers; male growth delay persisted.
Checked source or related source review ↗Новые подходы к терапии анемий гестационного периода
Belokrinitskaya & Kuznik. 1993. Russian Bulletin of Perinatology and Pediatrics 38(6):11–13 in author bibliography
Original journal pages needed
Pagination varies between bibliographies. Related 1995 dissertation data are labeled separately; not an additional verified patient cohort.
Checked source or related source review ↗Оптимизация иммунокорригирующей терапии у беременных с латентными герпес-вирусными инфекциями
Vladimirova, Nikitin & Chizhova. 2023. Healthcare of the Far East (2):43–48. DOI 10.33454/1728-1261-2023-2-43-48
Publisher full text and table text checked
112-woman dataset labeled 2017 in the 2023 paper. Only the 36-woman middle-risk protocol explicitly adds Imunofan; whole-program outcomes are not its isolated effect.
Checked source or related source review ↗Влияние коротких пептидов на поведение и латентное обучение крыс, перенесших пренатальную гипоксию
Mendzheritskii, Karantysh, Abramchuk & Ryzhak. VIII Sudak Congress, 2012, p.276
Conference lead; original page not recovered
Pinealon/Cortexin program. Proceedings endpoint timed out; no numerical findings attributed to this abstract. See the separately labeled 2013 dissertation and recovered 2014 proceedings.
Влияние коротких пептидов на содержание моноаминов в мозге крыс, перенесших пренатальную гипоксическую гипоксию
Mendzheritskii et al. VIII Sudak Congress, 2012, p.277
Conference lead; original page not recovered
Likely related to the same Rostov program, but sample overlap and numerical results require the actual page.
Влияние пептидных препаратов на показатели устойчивости к пренатальному стрессу
Mendzheritskii & Karantysh. X Sudak Congress, 2014, pp.233–234
Original proceedings pages visually checked
Pinealon, Cortexin and Deltaran maternal exposure. Survival percentages lack denominators; conflicting caspase-3 statements retained.
Checked source or related source review ↗Тимоген как корректор системы эритрона при гестационных анемиях
Belokrinitskaya. Peptide Bioregulators: Cytomedins symposium. St. Petersburg, 1992, pp.20–21
Citation lead in dissertation bibliography
Original symposium abstract still needed; not counted as a separate clinical confirmation.
Checked source or related source review ↗Mechanisms of Prenatal Hyperhomocysteinemia Neurotoxicity: The Effect on the Offspring
Arutjunyan, Kozina, Milyutina & Korenevsky. FEBS Journal 280(Suppl.1), 2013, p.347
Conference citation pending verification
Original abstract not recovered. A peptide intervention, dose and treatment result cannot be established from this citation.
Коррекция пинеалоном нарушенного в условиях экспериментальной гипергомоцистеинемии суточного ритма содержания норадреналина в гипоталамусе самок крыс
Korenevskii et al. Neurochemistry conference, St. Petersburg–Koltushi, 2014, p.76
Conference citation; related journal abstract checked
Original conference page still needed. Nonpregnant reproductive physiology; related journal source is reference 22.
Checked source or related source review ↗Протекторное влияние мелатонина и пептидного препарата эпиталона на гипоталамическую регуляцию репродуктивной функции самок крыс…
Korenevskii et al. Advances in Gerontology 27(2), supplement, 2014, p.42
Bibliographic lead; complete title/page needed
Nonpregnant reproductive-regulation trail. Citation does not establish pregnancy exposure or an isolated Epitalon outcome.
Melatonin and Pineal Gland Peptides Are Able to Correct the Impairment of Reproductive Cycles in Rats
Arutjunyan et al. 2012. Current Aging Science 5(3):178–185. PMID 23237594
Original indexed abstract checked
DMH xenobiotic model, not pregnancy. Epitalon and Epithalamin are different preparations.
Checked source or related source review ↗Pinealon Corrects Hyperhomocysteinemia-Induced Disturbances of the Diurnal Dynamics of Hypothalamic Norepinephrine Content in Female Rats
Korenevskii et al. 2014. Neurochemical Journal 8(3):205–207. DOI 10.1134/S1819712414030088
Publisher abstract and metadata checked
Methionine-loaded female-rat neurochemistry; no verified pregnancy, live-birth or human fertility outcome.
Checked source or related source review ↗Возрастные нарушения гипоталамической регуляции репродуктивных циклов и их коррекция
Arutjunyan & Korenevskii. 2014. Advances in Gerontology 27(2):275–283
Bibliographic lead; original review needed
Reproductive-cycle review, not an independently verified pregnancy trial. Full original text needed before extracting outcomes.
Тимоген в акушерско-гинекологической практике
Dolgov & Smirnov. Bibliographic year 2007; retrieved title page does not show the year
Original monograph text checked
Secondary summaries; source cohorts and unit/transcription discrepancies are explicit. Not a new trial.
Checked source or related source review ↗Клинико-иммунологическое обоснование применения тимогена и спленина в терапии хронического пиелонефрита и анемии у беременных
Huda Saleh Omar. Tashkent, 1992
Dissertation author-abstract lead
Original scan, group sizes, separate Thymogen/Splenin arms and safety follow-up still needed. A bibliography mention is not a verified treatment result.
Влияние неопиатного аналога лей-энкефалина и пептидного морфогена гидры на синтез ДНК и процессы перекисного окисления липидов в системе органов дыхания новорожденных крыс, подвергнутых пренатальной гипоксии
O. A. Lebedko. Khabarovsk, 1994
Author-abstract transcription checked
Maternal peptide exposure, 160 dams in the program. OCR sequence ambiguity and unverified table scan; Hydra morphogen is a separate molecule.
Checked source or related source review ↗Иммуногенетические аспекты этиопатогенеза, прогнозирования и профилактики гестационных анемий
T. E. Belokrinitskaya. Doctoral dissertation, Irkutsk, 1995; Chita program
Author-abstract transcription checked
520-woman overall program; overlapping subsets; 12 versus 12 Thymalin prevention comparison. Complete original 313-page thesis still needed.
Checked source or related source review ↗Гистогенез лимфоидных органов при воздействии некоторых иммуномодуляторов
V. S. Ivanov. Veterinary-sciences dissertation, St. Petersburg, 2003
Dissertation title confirmed in university history
Thymogen and B-activin are possible interventions. Original methods needed to establish species, prenatal timing and preparation-specific findings.
Прогнозирование невынашивания беременности. Оптимизация ведения женщин с невынашиванием беременности в анамнезе
E. M. Filatova. Moscow, 2004
Dissertation catalogue lead
Imunofan is a possible intervention. Treatment groups and patient outcomes require confirmation from the dissertation.
Изменения клеточного иммунитета при гестозах беременных и их коррекция
N. B. Markelova. Volgograd, 2004
Author-abstract archive lead
Thymalin assignment, allocation, concurrent therapy and clinical endpoints require the original methods; immune-marker change alone is not obstetric efficacy.
Профилактика невынашивания беременности у женщин с микотической инфекцией половых путей
V. I. Chepanova / Chelanova in the archive transcription, 2008; original spelling requires confirmation
Author-abstract archive lead; spelling discrepancy
The archive transcription renders the author as Челанова Виктория Ивановна, while a separate bibliographic entry gives Chepanova. Verify the original title page, Imunofan methods and clinical outcome table.
Отдаленные последствия пренатального воздействия свинца на головной мозг крыс и влияние на них препаратов с антиоксидантными свойствами
D. S. Belolyubskaya. 2008
Dissertation catalogue lead
Epitalon is a possible exposure. Confirm treatment timing, comparators and long-term findings against the original tables.
Антиоксидантное действие геропротекторных пептидных биорегуляторов
L. S. Kozina. 2009
Dissertation archive lead
Pinealon and related peptides; complete methods, original tables and overlap with the 2008/2012 papers remain acquisition targets.
Пептидная регуляция нейродегенеративных процессов у молодых и старых крыс
V. A. Abramchuk. St. Petersburg, 2013
Author-abstract transcription checked
Prenatal and older-animal arms separated. Table denominators unresolved; source is not an authenticated full dissertation.
Checked source or related source review ↗Онтогенетические особенности поведенческих реакций и функциональных изменений в мозге крыс в моделях ишемии/гипоксии
G. V. Karantysh. 2014
Institutional full-thesis link located; not appraised
Pinealon, Cortexin and Deltaran research trail. Institutional PDF retrieval timed out; no new numerical findings extracted from it.
Нарушение гипоталамической регуляции репродуктивных циклов при воздействии неблагоприятных экологических факторов
A. V. Korenevskii. St. Petersburg, 2015
Dissertation catalogue lead
Nonpregnant cycle-regulation research. Complete methods needed to separate Pinealon, Epitalon, Epithalamin and melatonin arms; not pregnancy-safety evidence.
What the next source recovery needs to resolve
- Obtain the full Kozina, Abramchuk and Karantysh dissertations, their original tables and dam/litter accounting; reconcile overlapping conference and journal cohorts.
- Recover the two 2012 Sudak abstract pages and the 1993 anemia article, with correct pagination and treatment-arm definitions.
- Resolve the 2014 Deltaran caspase-3 contradiction and missing untreated-hypoxia comparator; clarify whether its reported dose is formulation or peptide mass.
- Authenticate the original Lebedko tables and sequence, and retrieve the Omar, Markelova, Filatova and Chelanova methods before assigning compound-specific patient outcomes.
- For every maternal exposure, seek allocation methods, masking, litter-adjusted analysis, fetal loss, malformations, placental transfer, maternal harms and follow-up beyond the selected developmental tests.
- For human bundled care, recover raw counts and comparable untreated groups. Biomarker changes and overall program percentages cannot isolate one peptide.
Questions about peptides and pregnancy
Is Pinealon safe during pregnancy?
The studies reviewed here do not establish safety in human pregnancy. Maternal rat experiments report selected offspring benefits after injury, but lack a healthy-treatment arm in the 2012 study, adequate reproductive-safety surveillance and human follow-up. Homocysteine remained elevated despite improvement in some outcomes.
What did the Epitalon pregnancy paper actually find?
In a small late-gestation rat experiment, offspring showed larger selected brain measurements, lower body weight at day 40 and less exploratory, more anxiety-related behavior at day 30. The structural findings should not be advertised as proven brain improvement.
Were Semax and Cortexin given to pregnant animals or to offspring?
Both study types exist. The maternal Semax reports name a peptide combination. The Sudak Cortexin comparison gave treatments to pregnant dams, whereas the 2016 Cortexin hypoxic-ischemic experiment treated seven-day-old pups. Exposure timing must be checked paper by paper.
2001 source and results ↗ 2014 source and results ↗ 2016 source and results ↗
Do the human Thymalin, Thymogen and Imunofan reports prove pregnancy safety?
No. They document historical exposure and selected outcomes in small, uncontrolled or confounded programs. Missing adverse-event ascertainment, incomplete follow-up and combined treatment prevent a reliable compound-specific safety or efficacy conclusion.
1995 source and results ↗ 2023 source and results ↗ 2007 source and results ↗
Are Epitalon and Epithalamin interchangeable?
Epitalon, also spelled Epithalon, is the defined AEDG tetrapeptide. Epithalamin is a pineal tissue-derived peptide mixture. The reproductive-cycle paper describes region-specific effects for each; an extract’s clinical or animal result cannot be assigned to isolated Epitalon.
Why list papers whose full text is still missing?
They preserve a traceable research trail while making the evidence gap explicit. The archive below distinguishes checked original PDFs, accessible abstracts, secondary summaries and unretrieved citations. A bibliography lead is not counted as a completed trial or given invented results.
Explore the compound-specific evidence
NALE & peptide G → Pinealon → Epitalon → Cortexin → DSIP → Semax → Thymalin → Thymogen → Imunofan → Epithalamin → Glyprolins & PGP hybrids → Selank → Dalargin → Vilon → Vesugen →
Full bibliography and PDF links ↗ · How Molekul reviews evidence ↗
Curated by Molekul / @PepMariner. Source review describes the materials inspected; it is not an independent clinical audit or specialist obstetric review.